Interferon Beta-1b — Membership Pricing

Other medications in Neurological

• Lacosamide
• Lasmiditan
• Meclizine
• Memantine
• Midazolam Nasal
• Natalizumab (Neurology)
• Nusinersen
• Ocrelizumab

About Interferon Beta-1b

Multiple Sclerosis (MS) is a chronic, often debilitating disease that attacks the central nervous system. For many, Interferon Beta 1b offers a beacon of hope, playing a crucial role in managing the disease's progression and reducing the frequency of relapses.

What Interferon Beta 1b Treats

Interferon Beta 1b is primarily used to treat relapsing forms of Multiple Sclerosis, including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). Its goal is not to cure MS, but to reduce the number and severity of relapses, slow down disease progression, and decrease the accumulation of lesions in the brain and spinal cord, as seen on MRI scans. This can significantly improve a patient's quality of life and long-term prognosis.

How Interferon Beta 1b Works

As an immunomodulator, Interferon Beta 1b works by interacting with the immune system. In MS, the immune system mistakenly attacks the myelin sheath, the protective covering around nerve fibers. Interferon Beta 1b helps to regulate this immune response, reducing inflammation and nerve damage. It's thought to decrease the number of immune cells that cross the blood-brain barrier and limit the production of inflammatory substances, thereby protecting nerve cells and slowing the disease's progression. It's typically administered via subcutaneous injection.

Typical Costs of Interferon Beta 1b

Medications for chronic conditions like MS often come with a significant price tag, and Interferon Beta 1b is no exception. Without insurance, the cost of Interferon Beta 1b can be thousands of dollars per month, making it one of the more expensive treatments on the market. Prices can vary based on the specific brand (e.g., Betaseron, Extavia), dosage, and the pharmacy where it's purchased. Even with insurance, co-pays and deductibles can accumulate quickly, posing a substantial financial burden for many patients and families.

How TheDrugClub Can Help You Save

Navigating the high costs of essential medications like Interferon Beta 1b can be daunting, but TheDrugClub is here to help. As a member, you gain access to a powerful network of pharmacies offering discounted prices on thousands of prescription

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Interferon Beta-1b is approved for (FDA label)

BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BETASERON is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: March 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Interferon Beta-1b (FDA label)

For injection: 0.3 mg lyophilized powder in a single-dose vial for reconstitution. For injection: 0.3 mg of lyophilized powder in a single-dose vial for reconstitution ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 66311f74-0472-4fa3-848a-06002ca0def5. SPL document ID: 4ebf941b-8ad4-4faa-83d6-550b526270e9. Label effective date: March 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Interferon Beta-1b (FDA label)

The following serious adverse reactions are discussed in more details in other sections of labeling: • Hepatic Injury [see Warnings and Precautions ( 5.1 )] • Anaphylaxis and Other Allergic Reactions [see Warnings and Precautions ( 5.2 )] • Depression and Suicide [see Warnings and Precautions ( 5.3 )] • Congestive Heart Failure [see Warnings and Precautions ( 5.4 )] • Injection Site Reactions Including Necrosis [see Warnings and Precautions ( 5.5 )] • Leukopenia [see Warnings and Precautions ( 5.6 )] • Thrombotic Microangiopathy [see Warnings and Precautions ( 5.7 )] • Pulmonary Arterial Hypertension [see Warnings and Precautions ( 5.8 )] • Flu-like Symptom Complex [see Warnings and Precautions ( 5.9 )] • Seizures [see Warnings and Precautions ( 5.10 )] • Drug Induced Lupus Erythematosus [see Warnings and Precautions ( 5.11 )] In controlled clinical trials, the most common adverse reactions (at least 5% more frequent on BETASERON than on placebo) were: injection site reaction, lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, increased liver enzymes, headache, hypertonia, pain, rash, insomnia, abdominal pain, and asthenia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions and over varying lengths of time, adverse reaction rates observed in the clinical trials of BETASERON cannot be directly compared to rates in clinical trials of other drugs, and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 66311f74-0472-4fa3-848a-06002ca0def5. SPL document ID: 4ebf941b-8ad4-4faa-83d6-550b526270e9. Label effective date: March 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Interferon Beta-1b (FDA label)

BETASERON is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, Albumin (Human), or any other component of the formulation. History of hypersensitivity to natural or recombinant interferon beta, albumin or mannitol ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 66311f74-0472-4fa3-848a-06002ca0def5. SPL document ID: 4ebf941b-8ad4-4faa-83d6-550b526270e9. Label effective date: March 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Interferon Beta-1b (FDA label)

• Hepatic Injury: Monitor liver function tests and signs and symptoms of hepatic injury; consider discontinuing BETASERON if serious hepatic injury occurs. ( 5.1 , 5.11 ) • Anaphylaxis and Other Allergic Reactions: Discontinue if anaphylaxis occurs. ( 5.2 ) • Depression and Suicide: Advise patients to immediately report any symptom of depression and/or suicidal ideation; consider discontinuation of BETASERON if depression occurs. ( 5.3 ) • Congestive Heart Failure (CHF): Monitor patients with CHF for worsening of cardiac symptoms; consider discontinuation of BETASERON if worsening of CHF occurs. ( 5.4 ) • Injection Site Reactions Including Necrosis: Do not administer BETASERON into affected area until fully healed; if multiple lesions occur, change injection site or discontinue BETASERON until healing of skin lesions. ( 5.5 ) • Leukopenia: Monitor complete blood count. ( 5.6 , 5.12 ) • Thrombotic Microangiopathy: Cases of thrombotic microangiopathy (TMA) have been reported.

Source: FDA prescribing information (DailyMed). Set ID: 66311f74-0472-4fa3-848a-06002ca0def5. SPL document ID: 4ebf941b-8ad4-4faa-83d6-550b526270e9. Label effective date: March 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.